メインナビゲーションにスキップ
検索にスキップ
メインコンテンツにスキップ
富山大学 ホーム
日本語
English
ホーム
プロファイル
研究部門
プロジェクト
研究成果
データセット
受賞
活動
コース
専門知識、名前、または所属機関で検索
Scopus著者プロファイル
貝沼 茂三郎
教授, 博士（医学） 富山医科薬科大学 2003年8月
和漢診療学講座
h-index
845
被引用数
17
h 指数
Pureの文献数とScopusの被引用数に基づいて算出されます
2004
2025
年別の研究成果
概要
フィンガープリント
ネットワーク
プロジェクト
(2)
研究成果
(17)
コース
(11)
類似のプロファイル
(6)
フィンガープリント
Mosaburo Kainumaが活動している研究トピックを掘り下げます。このトピックラベルは、この研究者の研究成果に基づきます。これらがまとまってユニークなフィンガープリントを構成します。
並べ替え順
重み付け
アルファベット順
Keyphrases
Chronic Hepatitis C
100%
Kampo Medicine
53%
Kampo
46%
Sustained Virological Response
41%
Hepatitis C
40%
Ribavirin
33%
Pegylated Interferon
32%
Herbal Medicine
32%
Interferon-α (IFN-α)
29%
Ribavirin Treatment
28%
Kyushu
25%
Population-based Study
24%
Okinawa
23%
Japan
22%
AIDS/HIV
21%
Hachimijiogan
20%
Virological Response
20%
Keishibukuryogan
18%
Traditional Japanese Medicine
18%
Telaprevir
17%
Triple Therapy
17%
IL28B
17%
Hepatitis C Virus
17%
Combination Therapy
16%
Genotype 1
16%
Hepatitis C Virus RNA
15%
Antiviral Treatment
15%
Hepatitis C Virus Genotypes
14%
Integrative Management
14%
Epidemic Disease
14%
Pegylated Interferon alfa-2a
12%
Human Immunodeficiency Virus Infection
12%
Homeostasis Model Assessment of Insulin Resistance (HOMA-IR)
12%
Japanese Population
12%
Insulin Resistance
11%
Non-alcoholic Fatty Liver Disease (NAFLD)
11%
Genotype
11%
Mild Alzheimer's Disease
11%
Escherichia Coli Infections
11%
Antiretroviral Therapy
11%
COVID-19
11%
Chronic Hepatitis C Virus Infection
10%
Odds Ratio
10%
Japanese Workers
10%
Kampo Formula
9%
Abbott RealTime
9%
Rs8099917
9%
Azithromycin
9%
Response Rate
9%
Tongue Color
9%
Pharmacology, Toxicology and Pharmaceutical Science
Chronic Hepatitis C
95%
Kampo Medicine (Drug)
66%
Interferon
36%
Ribavirin
36%
Peginterferon
34%
Hepatitis C Virus
28%
Antivirus Agent
22%
Disease
20%
Telaprevir
17%
Population Study
17%
Leporidae
17%
Combination Therapy
15%
Virus RNA
14%
HIV
13%
Infection
13%
Keishi Bukuryo Gan
13%
Hachimijiogan
11%
Escherichia Coli Infection
11%
Alzheimer's Disease
11%
Mixed Infection
11%
Nonalcoholic Fatty Liver
10%
Randomized Controlled Trial
9%
Adverse Event
9%
Interleukin 28B
8%
Azithromycin
8%
Chronic Hepatitis B
8%
Alanine Aminotransferase
7%
Alpha Tocopherol
7%
Xiao Chai Hu Tang
7%
Liver Injury
7%
Alpha2b Interferon Plus Ribavirin
7%
Peginterferon Alpha2b
7%
Atherosclerosis
6%
Insulin Resistance
6%
Immune Reconstitution Inflammatory Syndrome
5%
Shiga Toxin Producing Escherichia Coli
5%
Toxic Hepatitis
5%
Fibrosis
5%
Shiga Toxin
5%
Thrombocytopenia
5%
Fatty Liver
5%
Brain Natriuretic Peptide
5%
Acquired Immune Deficiency Syndrome
5%
Helicobacter Infection
5%
Syndrome
5%
Hepatotoxicity
5%
Impaired Glucose Tolerance
5%
Hepatitis B Antigen
5%
Binding Protein
5%
Orengedoku to
5%
Medicine and Dentistry
Kampo
67%
Chronic Hepatitis C
58%
Homeopathy
26%
Interferon
23%
Ribavirin
20%
Keishi Bukuryo Gan
20%
Peginterferon
20%
Hepatitis C Virus
19%
Population Research
17%
Disease
16%
Human Immunodeficiency Virus
13%
Combination Therapy
13%
Antiviral Therapy
12%
Nonalcoholic Fatty Liver
11%
COVID-19
11%
Tongue
11%
Infection
10%
Urinary System
10%
Pylorus
9%
Atherosclerosis
9%
Virus RNA
8%
Randomized Controlled Trial
8%
Alzheimer's Disease
8%
Hachimijiogan
8%
Drug Therapy
8%
Triacylglycerol
8%
Alpha Tocopherol
8%
Adverse Event
8%
Injury
7%
Highly Active Antiretroviral Therapy
7%
Xiao Chai Hu Tang
7%
Edema
7%
Liver Injury
7%
Steatohepatitis
6%
Hypertriglyceridemia
6%
Fibrosis
6%
Physician
6%
Body Mass Index
5%
Odds Ratio
5%
Oxidative Stress
5%
Sensitivity and Specificity
5%
Glucose Tolerance
5%
Subacute Thyroiditis
5%
Fatty Liver
5%
Leadership
5%
Peripheral Lymphocyte
5%
Lymphocyte Subpopulation
5%
Population
5%
Impaired Glucose Tolerance
5%
Arthritis
5%
